• Product name

    Anti-GLP1 antibody [EPR4043]
    See all GLP1 primary antibodies
  • Description

    Rabbit monoclonal [EPR4043] to GLP1
  • Host species

  • Tested applications

    Suitable for: IHC-Pmore details
    Unsuitable for: Flow Cyt,ICC,IP or WB
  • Species reactivity

    Reacts with: Mouse, Human
    Predicted to work with: Rat
  • Immunogen

    Synthetic peptide corresponding to residues in Human GLP1 (UniProt P01275).

  • Positive control

    • Human pancreas tissue.
  • General notes



    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab133329 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/250 - 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
  • Application notes
    Is unsuitable for Flow Cyt,ICC,IP or WB.
  • Target

    • Function

      Glucagon plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes.
      GLP-1 is a potent stimulator of glucose-dependent insulin release. Play important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Have growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferaton. Inhibits beta cell apoptosis.
      GLP-2 stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability.
      Oxyntomodulin significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness.
      Glicentin may modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life.
    • Tissue specificity

      Glucagon is secreted in the A cells of the islets of Langerhans. GLP-1, GLP-2, oxyntomodulin and glicentin are secreted from enteroendocrine cells throughout the gastrointestinal tract. GLP1 and GLP2 are also secreted in selected neurons in the brain.
    • Sequence similarities

      Belongs to the glucagon family.
    • Post-translational

      Proglucagon is post-translationally processed in a tissue-specific manner in pancreatic A cells and intestinal L cells. In pancreatic A cells, the major bioactive hormone is glucagon cleaved by PCSK2/PC2. In the intestinal L cells PCSK1/PC1 liberates GLP-1, GLP-2, glicentin and oxyntomodulin. GLP-1 is further N-terminally truncated by post-translational processing in the intestinal L cells resulting in GLP-1(7-37) GLP-1-(7-36)amide. The C-terminal amidation is neither important for the metabolism of GLP-1 nor for its effects on the endocrine pancreas.
    • Cellular localization

    • Information by UniProt
    • Database links

    • Alternative names

      • GCG antibody
      • glicentin-related polypeptide antibody
      • GLP-1 antibody
      • GLP-1(7-36) antibody
      • GLP-1(7-37) antibody
      • GLP-2 antibody
      • GLP1 antibody
      • GLP1, included antibody
      • GLP2 antibody
      • GLP2, included antibody
      • GLUC_HUMAN antibody
      • Glucagon antibody
      • Glucagon like peptide 1 antibody
      • glucagon-like peptide 1 antibody
      • Glucagon-like peptide 1, included antibody
      • Glucagon-like peptide 2 antibody
      • Glucagon-like peptide 2, included antibody
      • GRPP antibody
      • OXM antibody
      • OXY antibody
      • preproglucagon antibody
      see all


    • Immunohistochemical analysis of paraffin-embedded Human pancreas tissue labelling GLP1 with ab133329 at 1/250 dilution.
    • ab133329 showing negative staining in Normal colon tissue.

    • ab133329 showing negative staining in Normal liver tissue.

    • ab133329 showing positive staining in Pancreas tissue.

    • ab133329 showing negative staining in Normal tonsil tissue.

    • ab133329 showing negative staining in Normal breast tissue.

    • ab133329 showing negative staining in Normal kidney tissue.


    This product has been referenced in:

    • Hernández C  et al. Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes. Diabetes 65:172-87 (2016). Read more (PubMed: 26384381) »
    • Mi B  et al. Non-invasive glucagon-like peptide-1 receptor imaging in pancreas with (18)F-Al labeled Cys(39)-exendin-4. Biochem Biophys Res Commun 471:47-51 (2016). IHC-P ; Rat . Read more (PubMed: 26850848) »
    See all 3 Publications for this product

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab133329.
    Please use the links above to contact us or submit feedback about this product.

    For licensing inquiries, please contact partnerships@abcam.com

    Sign up